BGI, in collaboration with Institute of Biophysics, Chinese Academy of Sciences, and other Chinese institutes, have completed the genome sequencing of 161 Mycobacterium tuberculosis. The study published online in Nature Genetics provides an invaluable resource for researchers to better understand the genetic basis underlying drug-resistant TB.
TB is one of the deadliest infectious diseases. The World Health Organization estimates that one-third of the world's population is infected with M. tuberculosis. Although TB control efforts have made an encouraging 1.3 percent decline in TB incidence worldwide each year since 2002, drug-resistant TB is still a serious and growing global challenge for treatment. The drug resistance is particularly acute in China, where 5.7 percent of new TB cases are multidrug-resistant (MDR), and 8 percent of MDR cases are extensively drug-resistant (XDR).
To understand the drug resistance mechanism from DNA level, Chinese researchers conducted a comprehensive genome-wide study of 161 M. tuberculosis strains with a broad range of resistance profiles (44 drug-sensitive, 94 MDR and 23 XDR isolates). In total, they discovered 72 novel genes, 28 intergenic regions (IGRs), 11 nonsynonymous SNPs and 10 IGR SNPs with strong, consistent associations with drug resistance.
Researchers found that the genetic basis of drug resistance is more complex than previously expected. The identification of new drug resistanceassociated genes, IGRs and SNPs provides a nearly complete gene set for studying drug resistance TB. These findings lay a solid foundation for the in-depth investigation of the drug resistance mechanisms in both M. tuberculosis and other bacterial pathogens treated with the same antibiotic regimens.
Dongfang Li, Project manager from BGI, says, "The drug resistance of M. tuberculosis is a very serious problem, especially in China. We expect our breakthrough can shed new insights for exploring the mechanisms of drug resistance, and lay a solid foundation for the control and protection against TB.